Voya Investment Management LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Voya Investment Management LLC

$79.9 Billion
Q3 2024

A detailed history of Voya Investment Management LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 289,699 shares of ARWR stock, worth $5.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

289,699

Previous 266,062 8.88%

Holding current value

$5.69 Million

Previous $6.91 Million 18.89%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $457,612 - $698,236	23,637 Added 8.88%	289,699 $5.61 Million
Q2 2024 Dec 03, 2024	SELL	$21.87 - $28.24 $516,941 - $667,508	-23,637 Reduced 8.16%	266,062 $6.91 Million
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $1.84 Million - $2.38 Million	84,174 Added 46.28%	266,062 $6.91 Million
Q1 2024 Dec 06, 2024	SELL	$27.21 - $39.48 $2.93 Million - $4.26 Million	-107,811 Reduced 37.21%	181,888 $5.2 Million
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $162,879 - $236,327	-5,986 Reduced 3.19%	181,888 $5.2 Million
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $168,010 - $245,912	7,925 Added 4.4%	187,874 $5.75 Million
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $1.1 Million - $1.52 Million	-42,022 Reduced 18.93%	179,949 $4.84 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $214,790 - $353,261	-8,537 Reduced 3.7%	221,971 $7.92 Million
Q1 2023 May 15, 2023	SELL	$23.68 - $38.51 $625,270 - $1.02 Million	-26,405 Reduced 10.28%	230,508 $5.85 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $130,340 - $188,806	4,655 Added 1.85%	256,913 $10.4 Million
Q3 2022 Mar 03, 2023	SELL	$29.63 - $48.31 $137,927 - $224,883	-4,655 Reduced 1.81%	252,258 $8.34 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $715,475 - $1.17 Million	24,147 Added 10.59%	252,258 $8.34 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $2.17 Million - $3.95 Million	77,979 Added 51.94%	228,111 $8.03 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $1.73 Million - $3.06 Million	43,783 Added 41.17%	150,132 $6.91 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $9.41 Million - $13.4 Million	-161,964 Reduced 60.36%	106,349 $7.05 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $5,721 - $8,326	98 Added 0.04%	268,313 $16.8 Million
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $768,484 - $1.12 Million	-12,365 Reduced 4.41%	268,215 $22.2 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $930,495 - $1.37 Million	-15,167 Reduced 5.13%	280,580 $18.6 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $2.84 Million - $5.52 Million	-64,712 Reduced 17.95%	295,747 $22.7 Million
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $370,357 - $571,763	-11,152 Reduced 3.0%	360,459 $15.5 Million
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $2.65 Million - $4.38 Million	-101,322 Reduced 21.42%	371,611 $16 Million
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $808,336 - $2.48 Million	39,316 Added 9.07%	472,933 $13.6 Million
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $10.5 Million - $27.2 Million	373,124 Added 616.81%	433,617 $27.5 Million
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $4,936 - $6,553	-188 Reduced 0.31%	60,493 $1.71 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $409,064 - $676,376	23,469 Added 63.07%	60,681 $1.61 Million
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $12,809 - $21,451	1,063 Added 2.94%	37,212 $683,000
Q4 2018 Feb 14, 2019	BUY	$10.74 - $19.7 $23,101 - $42,374	2,151 Added 6.33%	36,149 $449,000
Q2 2018 Aug 14, 2018	BUY	$6.37 - $14.02 $216,567 - $476,651	33,998 New	33,998 $462,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.

Account

Voya Investment Management LLC Arrowhead Pharmaceuticals, Inc. Transaction History